In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, No. 4_suppl ( 2017-02-01), p. 763-763
Abstract:
763 Background: Anti-EGFR-antibody-based treatment is a standard of care in patients with RASwt metastatic colorectal cancer (mCRC). Right-sided mCRC is associated with frequent presence of KRAS mutation and with worse prognosis. Here we show the clinical outcome of 1 st , 2 nd , and 3 rd -line anti-EGFR therapy in KRASwt mCRC patients in the context of primary tumor location. Methods: Data from 3 national comprehensive cancer centers in the Czech Republic were collected prospectively from 01/2009 to 03/2016. A retrospective analysis of outcomes of 567 pts with KRASwt mCRC treated with anti-EGFR was performed. Right-sided colon was defined as coecum, ascending colon and transverse; while left-sided contains the splenic flexure, descending and sigmoid colon. The group of metastatic rectal cancer was analyzed separately. The primary objective was assessment of OS and PFS in 1 st , 2 nd , and 3 rd -line treatment of mCRC. OS and PFS were calculated using the Kaplan-Meier method and statistical significance was assessed using the log-rank test. Results: Right-sided tumor location was in 125 pts (22.0%), left-sided in 231 (40.7%) and rectal in 211 (37.2%). Median OS and PFS in months with 95% CI and log-rank test p-value are shown in a table. Conclusions: KRASwt mCRC patients with primary tumor in left-sided colon and rectum have comparable clinical outcome when treated with anti-EGFR-based therapy. In metastatic disease, primary right-sided KRASwt carcinoma is associated with short PFS and OS across all anti-EGFR-based treatment lines. The work was partially supported by Czech Ministry of Helth project no. 16-31966A and Technology Agency of the Czech Republic no. TA04010838. [Table: see text]
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2017.35.4_suppl.763
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2017
detail.hit.zdb_id:
2005181-5
Bookmarklink